Zevra Therapeutics, Inc., a rare disease company, and Acer Therapeutics Inc., a pharmaceutical company focused on development and commercialization of therapies for rare and life-threatening diseases, entered into a definitive agreement under which Zevra will acquire Acer for $91 million. The merger will expand Zevra’s rare disease portfolio, as well as increase and diversify its revenues with the addition of a U.S. commercial asset, OLPRUVA, indicated for the treatment of urea cycle di...